ReviewFrontiers in immunology2022
The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Reprogramming Inflammatory Macrophages with Specialized Pro-Resolving Lipid Mediators: A Novel Immunotherapeutic Strategy for Asthma.Biomedicines · 2026Review
- Airway epithelial dysfunction in asthma pathogenesis: epigenetic mechanisms, inflammatory crosstalk, and therapeutic opportunities.Frontiers in allergy · 2026Review
- An Optimized Feeder-Free Method for Isolation and Expansion of Functional ILC2s Isolated From Human Peripheral Blood.Journal of immunology research · 2026Article
- Modulation of lung CD11bChinese medicine · 2025Article
- Type 2 immunity in allergic diseases.Cellular & molecular immunology · 2025Review
- Cold temperature enhances innate eosinophilic airway inflammation via transient receptor potential ankyrin1.Frontiers in immunology · 2025Article
- The role of innate immune system in respiratory viral infection related asthma.Frontiers in cellular and infection microbiology · 2025Review
- Expression and Clinical Significance of IL-33 and IL-25 in Post-Irradiation Otitis Media with Effusion.Journal of inflammation research · 2025Article
- Stage-specific GATA3 induction promotes ILC2 development after lineage commitment.Nature communications · 2024Article
- Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases.The Journal of allergy and clinical immunology · 2024Review
- A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects.Frontiers in pharmacology · 2024Article
- Myeloid-derived suppressor cells in influenza virus-induced asthma exacerbation.Frontiers in immunology · 2024Article
- Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation.Experimental & molecular medicine · 2023Review
- Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Severe Asthmatic Responses: The Impact of TSLP.International journal of molecular sciences · 2023Review
- Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T helper type 2 cells (Th2 cells) and group 2 innate lymphoid cells (ILC2s) play an important role in the pathophysiology of asthma, including airway eosinophilic inflammation. ILC2s are activated by epithelial-derived cytokines [interleukin-25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP)] from airway epithelial cells, leading to the release of high amounts of type 2 cytokines, such as IL-5 and IL-13. ILC2s induce airway inflammation in an antigen-independent manner, and ILC2s are considered to be involved in the pathogenesis of asthma exacerbation. Furthermore, ILC2 activation might also confer steroid resistance. Many recent studies in humans and mice are increasingly demonstrating that the function of ILC2s is regulated not just by epithelial-derived cytokines but by a variety of cytokines and mediators derived from innate immune cells. Furthermore, the biologics targeting these cytokines and/or their receptors have been shown to reduce asthma exacerbations and improve lung function and quality of life in asthmatics. This article reviews the current treatment landscape for type 2 airway inflammation in asthma and discusses the therapeutic potential for targeting ILC2s.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.